Repository logo
 

von Hippel-Lindau Disease: an Update

Published version
Peer-reviewed

Change log

Authors

Maher, Eamonn R 
Sandford, Richard N 

Abstract

Abstract: Purpose of Review: In this review, we discuss the key molecular and clinical developments in VHL disease that have the potential to impact on the natural history of the disease and improve patient outcomes. Recent Findings: Identifiable mutations in VHL underlie most cases of VHL and define clear genotype-phenotype correlations. Detailed clinical and molecular characterisation has allowed the implementation of lifelong screening programmes that have improved clinical outcomes. Functional characterisation of the VHL protein complex has revealed its role in oxygen sensing and the mechanisms of tumourigenesis that are now being exploited to develop novel therapies for VHL and renal cancer. Summary: The molecular and cellular landscape of VHL-associated tumours is revealing new opportunities to modify the natural history of the disease and develop therapies. Drugs are now entering clinical trials and combined with improved clinical and molecular diagnosis, and lifelong surveillance programmes, further progress towards reducing the morbidity and mortality associated with VHL disease is anticipated.

Description

Funder: University of Cambridge

Keywords

Cancer Genomics (K Snape and H Hanson, Section Editors), Topical Collection on Cancer Genomics, Inherited, von Hippel-Lindau disease, Phaeochromocytoma, Renal cell carcinoma, Haemangioblastomas, VHL tumour suppressor gene

Journal Title

Current Genetic Medicine Reports

Conference Name

Journal ISSN

2167-4876

Volume Title

7

Publisher

Springer US